We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to Biogen (BIIB) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Read MoreHide Full Article
Wall Street analysts forecast that Biogen Inc. (BIIB - Free Report) will report quarterly earnings of $4 per share in its upcoming release, pointing to a year-over-year decline of 0.5%. It is anticipated that revenues will amount to $2.38 billion, exhibiting a decline of 3.1% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 0.3% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Given this perspective, it's time to examine the average forecasts of specific Biogen metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts forecast 'Revenue- Contract manufacturing, royalty and other revenue' to reach $145.22 million. The estimate indicates a change of -26.5% from the prior-year quarter.
Analysts expect 'Revenue- Product- Multiple Sclerosis- Tysabri- Total' to come in at $420.22 million. The estimate points to a change of -13% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenue- Anti-CD20 Therapeutic Programs' should arrive at $421.06 million. The estimate points to a change of -2.9% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenue- Product- Spinal Muscular Atrophy- Spinraza- Total' will likely reach $403.30 million. The estimate indicates a change of -7.7% from the prior-year quarter.
Analysts' assessment points toward 'Revenue- Product- Multiple Sclerosis- Tysabri- Rest of world' reaching $202.21 million. The estimate points to a change of -9.4% from the year-ago quarter.
The average prediction of analysts places 'Revenue- Product- Multiple Sclerosis- Tecfidera- Rest of world' at $192.16 million. The estimate indicates a year-over-year change of +2.4%.
The collective assessment of analysts points to an estimated 'Revenue- Product- Multiple Sclerosis- Tecfidera- United States' of $42.72 million. The estimate suggests a change of -35.8% year over year.
Analysts predict that the 'Revenue- Product- Spinal Muscular Atrophy- Spinraza- United States' will reach $153.96 million. The estimate indicates a year-over-year change of -1.2%.
The consensus among analysts is that 'Revenue- Product- Spinal Muscular Atrophy- Spinraza- Rest of World' will reach $248.15 million. The estimate indicates a year-over-year change of -11.8%.
According to the collective judgment of analysts, 'Revenue- Product- Multiple Sclerosis- Tysabri- United States' should come in at $217.40 million. The estimate indicates a year-over-year change of -16.4%.
The consensus estimate for 'Revenue- Product- Multiple Sclerosis- Vumerity- United States' stands at $134.08 million. The estimate points to a change of +2.9% from the year-ago quarter.
It is projected by analysts that the 'Revenue- Product- Multiple Sclerosis- Vumerity- Rest of World' will reach $21.15 million. The estimate points to a change of +33% from the year-ago quarter.
Shares of Biogen have demonstrated returns of -7.5% over the past month compared to the Zacks S&P 500 composite's +0.1% change. With a Zacks Rank #3 (Hold), BIIB is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Countdown to Biogen (BIIB) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Wall Street analysts forecast that Biogen Inc. (BIIB - Free Report) will report quarterly earnings of $4 per share in its upcoming release, pointing to a year-over-year decline of 0.5%. It is anticipated that revenues will amount to $2.38 billion, exhibiting a decline of 3.1% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 0.3% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Given this perspective, it's time to examine the average forecasts of specific Biogen metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts forecast 'Revenue- Contract manufacturing, royalty and other revenue' to reach $145.22 million. The estimate indicates a change of -26.5% from the prior-year quarter.
Analysts expect 'Revenue- Product- Multiple Sclerosis- Tysabri- Total' to come in at $420.22 million. The estimate points to a change of -13% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenue- Anti-CD20 Therapeutic Programs' should arrive at $421.06 million. The estimate points to a change of -2.9% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenue- Product- Spinal Muscular Atrophy- Spinraza- Total' will likely reach $403.30 million. The estimate indicates a change of -7.7% from the prior-year quarter.
Analysts' assessment points toward 'Revenue- Product- Multiple Sclerosis- Tysabri- Rest of world' reaching $202.21 million. The estimate points to a change of -9.4% from the year-ago quarter.
The average prediction of analysts places 'Revenue- Product- Multiple Sclerosis- Tecfidera- Rest of world' at $192.16 million. The estimate indicates a year-over-year change of +2.4%.
The collective assessment of analysts points to an estimated 'Revenue- Product- Multiple Sclerosis- Tecfidera- United States' of $42.72 million. The estimate suggests a change of -35.8% year over year.
Analysts predict that the 'Revenue- Product- Spinal Muscular Atrophy- Spinraza- United States' will reach $153.96 million. The estimate indicates a year-over-year change of -1.2%.
The consensus among analysts is that 'Revenue- Product- Spinal Muscular Atrophy- Spinraza- Rest of World' will reach $248.15 million. The estimate indicates a year-over-year change of -11.8%.
According to the collective judgment of analysts, 'Revenue- Product- Multiple Sclerosis- Tysabri- United States' should come in at $217.40 million. The estimate indicates a year-over-year change of -16.4%.
The consensus estimate for 'Revenue- Product- Multiple Sclerosis- Vumerity- United States' stands at $134.08 million. The estimate points to a change of +2.9% from the year-ago quarter.
It is projected by analysts that the 'Revenue- Product- Multiple Sclerosis- Vumerity- Rest of World' will reach $21.15 million. The estimate points to a change of +33% from the year-ago quarter.
View all Key Company Metrics for Biogen here>>>
Shares of Biogen have demonstrated returns of -7.5% over the past month compared to the Zacks S&P 500 composite's +0.1% change. With a Zacks Rank #3 (Hold), BIIB is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>